Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1AubagioProduct Name: TeriflunomidePharmaceutical Form: Capsule, hardINN or Proposed INN: TERIFLUNOMIDECAS Number: 108605-62-5Concentration unit: mg milligram(s)Concentration type: equalConcentration number: 14-Pharmaceutical form of the placebo: Capsule, hardRoute of administration of the placebo: Oral use----[1] 13 💬
2AubagioProduct Name: TeriflunomideProduct Code: HMR1726Pharmaceutical Form: Film-coated tabletINN or Proposed INN: TERIFLUNOMIDECAS Number: 108605-62-5Current Sponsor code: HMR1726Concentration unit: mg milligram(s)Concentration type: equalConcentration number: 14-Pharmaceutical form of the placebo: Film-coated tabletRoute of administration of the placebo: Oral use----[1] 13 💬
3Interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab[12] Acetate,
Alemtuzumab,
Cladribine,
Dimethyl fumarate,
Fingolimod,
Glatiramer,
Natalizumab,
Ocrelizumab,
Ofatumumab,
Ponesimod,
Rituximab,
Teriflunomide (Teriflunomide)		[13] Cladribine ,
Alemtuzumab ,
Rituximab ,
Dimethyl fumarate ,
Fingolimod hydrochloride ,
Glatiramer acetate ,
Ocrelizumab ,
Natalizumab ,
Ofatumumab ,
Fingolimod ,
Teriflunomide (Teriflunomide),
Ponesimod ,
Fingolimod lauryl sulfate 💬 		[26] DHODH,
HLA-A,
HLA-B,
HLA-C,
HLA-DMA,
HLA-DMB,
HLA-DOA,
HLA-DOB,
HLA-DPA1,
HLA-DPB1,
HLA-DQA1,
HLA-DQA2,
HLA-DQB1,
HLA-DRA,
HLA-DRB1,
HLA-DRB3,
HLA-DRB4,
HLA-DRB5,
HLA-E,
HLA-F,
HLA-G,
ITGA4,
KEAP1,
MS4A1,
RRM1,
S1PR1 💬 		[58] Allograft rejection, Antigen processing and presentation, Arrhythmogenic right ventricular cardiomyopathy, Asthma, Autoimmune thyroid disease, Cell adhesion molecule (CAM) interaction, Cellular senescence, Chemical carcinogenesis - reactive oxygen species, Cytoskeleton in muscle cells, Dilated cardiomyopathy, Drug metabolism - other enzymes, ECM-receptor interaction, Efferocytosis, Endocytosis, Epstein-Barr virus infection, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Glutathione metabolism, Graft-versus-host disease, Hematopoietic cell lineage, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IgSF CAM signaling, Inflammatory bowel disease, Influenza A, Integrin signaling, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Leukocyte transendothelial migration, Natural killer cell mediated cytotoxicity, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Pathways in cancer, Phagocytosis, Purine metabolism, Pyrimidine metabolism, Regulation of actin cytoskeleton, Rheumatoid arthritis, Sphingolipid signaling pathway, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Ubiquitin mediated proteolysis, Viral carcinogenesis, Viral myocarditis, Yersinia infection 💬[1] 13 💬
4Other: Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod[7] Acetate,
Fingolimod,
Glatiramer,
Ozanimod,
Ponesimod,
Siponimod,
Teriflunomide (Teriflunomide)		[10] Fingolimod hydrochloride ,
Glatiramer acetate ,
Fingolimod ,
Teriflunomide (Teriflunomide),
Ozanimod hydrochloride ,
Ozanimod ,
Siponimod fumarate ,
Ponesimod ,
Siponimod ,
Fingolimod lauryl sulfate 💬 		[26] DHODH,
HLA-A,
HLA-B,
HLA-C,
HLA-DMA,
HLA-DMB,
HLA-DOA,
HLA-DOB,
HLA-DPA1,
HLA-DPB1,
HLA-DQA1,
HLA-DQA2,
HLA-DQB1,
HLA-DRA,
HLA-DRB1,
HLA-DRB3,
HLA-DRB4,
HLA-DRB5,
HLA-E,
HLA-F,
HLA-G,
S1PR1,
S1PR2,
S1PR3,
S1PR4,
S1PR5 💬 		[37] Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecule (CAM) interaction, Cellular senescence, Efferocytosis, Endocytosis, Epstein-Barr virus infection, FoxO signaling pathway, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Neuroactive ligand-receptor interaction, Phagocytosis, Pyrimidine metabolism, Rheumatoid arthritis, Sphingolipid signaling pathway, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬[1] 13 💬
5Other: teriflunomide[1] Teriflunomide (Teriflunomide)[1] Teriflunomide (Teriflunomide) 💬 [1] DHODH 💬 [1] Pyrimidine metabolism 💬[1] 13 💬
6Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons)[4] Acetate,
Dimethyl fumarate,
Glatiramer,
Teriflunomide (Teriflunomide)		[3] Dimethyl fumarate ,
Glatiramer acetate ,
Teriflunomide (Teriflunomide) 💬 		[22] DHODH,
HLA-A,
HLA-B,
HLA-C,
HLA-DMA,
HLA-DMB,
HLA-DOA,
HLA-DOB,
HLA-DPA1,
HLA-DPB1,
HLA-DQA1,
HLA-DQA2,
HLA-DQB1,
HLA-DRA,
HLA-DRB1,
HLA-DRB3,
HLA-DRB4,
HLA-DRB5,
HLA-E,
HLA-F,
HLA-G,
KEAP1 💬 		[39] Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecule (CAM) interaction, Cellular senescence, Chemical carcinogenesis - reactive oxygen species, Endocytosis, Epstein-Barr virus infection, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Parkinson disease, Pathways in cancer, Phagocytosis, Pyrimidine metabolism, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Ubiquitin mediated proteolysis, Viral carcinogenesis, Viral myocarditis 💬[1] 13 💬
7TERIFLUNOMIDE[1] Teriflunomide (Teriflunomide)[1] Teriflunomide (Teriflunomide) 💬 [1] DHODH 💬 [1] Pyrimidine metabolism 💬[4] 13, 25, 26, 63 💬
8Teriflunomide (HMR1726)[1] Teriflunomide (Teriflunomide)[1] Teriflunomide (Teriflunomide) 💬 [1] DHODH 💬 [1] Pyrimidine metabolism 💬[1] 13 💬
9Teriflunomide 14 MG[1] Teriflunomide (Teriflunomide)[1] Teriflunomide (Teriflunomide) 💬 [1] DHODH 💬 [1] Pyrimidine metabolism 💬[1] 13 💬
10Teriflunomide 14 MG Oral Tablet [Aubagio][1] Teriflunomide (Teriflunomide)[1] Teriflunomide (Teriflunomide) 💬 [1] DHODH 💬 [1] Pyrimidine metabolism 💬[1] 13 💬
11Teriflunomide capsule[1] Teriflunomide (Teriflunomide)[1] Teriflunomide (Teriflunomide) 💬 [1] DHODH 💬 [1] Pyrimidine metabolism 💬[1] 13 💬
12TERIFLUNOMIDE HMR1726[1] Teriflunomide (Teriflunomide)[1] Teriflunomide (Teriflunomide) 💬 [1] DHODH 💬 [1] Pyrimidine metabolism 💬[1] 13 💬
13TeriflunomideProduct Code: HMR1726Pharmaceutical Form: Film-coated tabletINN or Proposed INN: TERIFLUNOMIDECAS Number: 108605-62-5Concentration unit: mg milligram(s)Concentration type: equalConcentration number: 14-Pharmaceutical form of the placebo: Film-coated tabletRoute of administration of the placebo: Oral useProduct Name: TeriflunomideProduct Code: HMR1726Pharmaceutical Form: Film-coated tabletINN or Proposed INN: TERIFLUNOMIDECAS Number: 108605-62-5Concentration unit: mg milligram(s)Concentration type: equalConcentration number: 7-Pharmaceutical form of the placebo: Film-coated tabletRoute of administration of the placebo: Oral useProduct Name: TeriflunomideProduct Code: HMR1726Pharmaceutical Form: Film-coated tabletINN or Proposed INN: TERIFLUNOMIDECAS Number: 108605-62-5Concentration unit: mg milligram(s)Concentration type: equalConcentration number: 3.5-Pharmaceutical form of the placebo: Film-coated tabletRoute of administration of the placebo: Oral use----[1] 13 💬